[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Hall8Jack Avatar @Hall8Jack Jack Hall

Jack Hall posts on X about $srpt, $dyn, $arwr, $rna the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks XXXXX% cryptocurrencies XXXX%

Social topic influence $srpt #9, $dyn #11, $arwr #5, $rna #2, events 2.94%, safety 2.94%, $vrtx 2.94%, $trda 2.94%, vrtx 2.94%, $nvs XXXX%

Top accounts mentioned or mentioned by @artsstocks @biotechanalysst @bikerieder @richtrades100 @rnaianalyst @commonsenseplay @jamesmclaw70633 @aistocksavvy @biopharmacaster @yachmod @biotecisfuture @timcarmichael3 @theprofessor85 @doepkemichel @sangamotx @titteridiot1 @singlemalt18 @morganstanley @avidresearch @jacobplieth

Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Dyne Therapeutics, Inc. Common Stock (DYN) Arrowhead Research Corporation (ARWR) Avidity Biosciences, Inc. Common Stock (RNA) Vertex Protocol (VRTX) Novartis AG (NVS)

Top Social Posts

Top posts by engagements in the last XX hours

"$dyn safety not as good as $srpt Etep. Srpt also had ppmo51 which was discontinued due to safety and dyne-251 is very close analog. I would scrutinize ongoing chronic safety data very closely. This safety is very mixed and read note 5- ie why did they choose not to report on safety events after 8/19/25"
X Link 2025-12-08T16:10Z 1640 followers, 1188 engagements

"$arwr Related to $srpt subQ CNS Ataxias/Huntingtons Disease programs:"
X Link 2025-12-10T14:59Z 1640 followers, 1422 engagements

"@RNAiAnalyst @JamesMclaw70633 $vrtx $trda also IV in DM1"
X Link 2025-11-15T19:00Z 1640 followers, XXX engagements

"@BikeRieder Do you know if this will be owned by $arwr or this is one of the $srpt agreed to programs"
X Link 2025-12-10T16:11Z 1640 followers, XXX engagements

"@BikeRieder Little bit surprised $nvs went with $arwr deal for aro-snca/PD instead of aro-mapt/AD. Do you think aro-mapt too expensive asset or nvs saw higher prob of success for aro-snca $Srpt also passed on aro-mapt (in favor of Ataxia1-3; HD CNS assets) so same type of question"
X Link 2025-12-07T13:53Z 1640 followers, XXX engagements

"@LSinnv @BikeRieder CNS SC Programs: aro-mapt/AD (arwr) aro-atxn1/Ataxia1 aro-atxn3/Ataxia3 aro-htt/HD (srpt) aro-snca/PD (nvs)"
X Link 2025-12-07T19:08Z 1640 followers, XXX engagements

"@richtrades100 @biopharmacaster $dyn safety for x51 looks worse than $srpt . Will be key consideration"
X Link 2025-12-08T11:53Z 1640 followers, XXX engagements

"$srpt / Endeavor cohort 8/sirolimus related (also $rgnx $sldb etc #GeneTherapy ) :"
X Link 2025-12-04T21:16Z 1640 followers, XXX engagements

"@richtrades100 @biopharmacaster Ppmo-51 had Mg problems. Not Eteplirsen. I stand by my statement. dyn51 had clinical hold. Not good for chronic tx. $dyn $srpt"
X Link 2025-12-08T11:58Z 1641 followers, XXX engagements

"@BiotechAnalysst Really need a detailed safety breakdown also"
X Link 2025-12-08T18:52Z 1640 followers, XXX engagements

"@BiotechAnalysst No new persistent thrombocytopenia for more than X months tough for a chronic tx. $dyn $rna $srpt"
X Link 2025-12-08T19:54Z 1640 followers, XXX engagements

"@bioinvestor24 Is this correct summary: $dyn dyne-251 produces 7fold increase of D over baseline $rna del-zota produces 4-5fold increase over baseline And according to this $srpt Etep produces 7fold increase over baseline"
X Link 2025-12-09T00:14Z 1640 followers, XXX engagements

"@FirstSquawk lol Nvda knew full well what was going on"
X Link 2025-12-10T18:17Z 1640 followers, XX engagements